Published 1/8/18 on Technical.ly/Baltimore
After years of development from the University of Maryland School of Medicine and a Columbia-based company, the GammaPod will be used for treatment in Baltimore in 2018.
After nearly a decade in development, a device to treat breast cancer that was developed at the University of Maryland School of Medicine has a key clearance toward going to market.
The U.S. Food and Drug Administration gave a 510(k) medical device clearance to the GammaPod, a device which treats early-stage breast cancer. The announcement was made in December.
“During radiation therapy, tumor cells are killed when their DNA is damaged by the radiation being absorbed into them. While radiation therapy has the potential to kill tumor cells, it can also damage healthy tissue around the tumor,” the FDA stated.
According to the University of Maryland-Baltimore, the device delivers a high dose of radiation to a tumor to a patient lying down, and reduces the amount of radiation that gets to breast tissue that is not impacted by the tumor and other organs.
“GammaPod uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a two-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation,” the FDA states.
It is not designed to replace Whole Breast Radiation Therapy, but the device could also reduce the time of the more targeted treatments from many weeks to less than a week.
“The GammaPod delivers a uniform dose to the tumor but the amount of radiation drops off rapidly outside the targeted area with a substantially reduced dose to healthy breast tissue,” Elizabeth M. Nichols, an assistant professor of radiation oncology at UMSOM who led a feasibility and safety study of the device in 2016, said in a statement. “We believe that this reduced exposure will result in better cosmetic outcomes for patients.”
The path for the device to date shows one local pathway toward bringing such a device to market. The GammaPod was invented by scientists at the University of Maryland School of Medicine in Baltimore including radiation oncology professor William F. Regine. The prototype was tested at the University of Maryland Medical Center. Columbia-based Xcision Medical Systems handled manufacturing, and applied for the FDA clearance to bring the device to market.
While clinical trials will continue to investigate further uses, the first treatment is expected to be offered at UM Medical Center in spring 2018.